ZOC2019619

ZOC2019619 is a first-in-class innovative ophthalmic drug developed as an eye drop formulation for the treatment of primary open-angle glaucoma (POAG) and ocular hypertension (OHT). It is currently in phase II clinical trials, where its efficacy and safety are being evaluated against both placebo and timolol eye drops. The drug aims to address unmet needs in glaucoma therapy, particularly within China, by providing a novel mechanism or approach distinct from existing treatments. The specific molecular target or mechanism of action has not been publicly disclosed as of June 2025. ZOC2019619 is being developed by Guangzhou Runer Ophthalmic Biotechnology Co., Ltd., with significant contributions from Zhongshan Ophthalmic Center at Sun Yat-sen University[1][2][3][4][5].